Abstract:Background: Alzheimer disease (AD) affects at least 5 million individuals in the USA alone stimulating an intense search for disease prevention and treatment therapies as well as for diagnostic techniques allowing early identification of AD during a long pre-symptomatic period that can be used for the initiation of prevention trials of disease-modifying therapies in asymptomatic individuals.Methods: Our approach to developing such techniques is based on the Gradient Echo Plural Contrast Imaging (GEPCI) technique that provides quantitative in vivo measurements of several brain-tissue-specific characteristics of the gradient echo MRI signal (GEPCI metrics) that depend on the integrity of brain tissue cellular structure.Preliminary data were obtained from 34 participants selected from the studies of aging and dementia at the Knight Alzheimer's Disease Research Center at Washington University in St. Louis. Cognitive status was operationalized with the Clinical Dementia Rating (CDR) scale. The participants, assessed as cognitively normal (CDR=O; n=23) or with mild AD dementia (CDR=0.5 or 1; n=11) underwent GEPCI MRI, a collection of cognitive performance tests and CSF amyloid (A beta) biomarker A beta(42). A subset of 19 participants also underwent PET PiB studies to assess their brain A beta burden. According to the Ap status, cognitively normal participants were divided into normal (A beta negative; n=13) and preclinical (A beta positive; n=10) groups.Results: GEPCI quantitative measurements demonstrated significant differences between all the groups: normal and preclinical, normal and mild AD, and preclinical and mild AD. GEPCI quantitative metrics characterizing tissue cellular integrity in the hippocampus demonstrated much stronger correlations with psychometric tests than the hippocampal atrophy. Importantly, GEPCI-determined changes in the hippocampal tissue cellular integrity were detected even in the hippocampal areas not affected by the atrophy.Our studies also uncovered strong correlations between GEPCI brain tissue metrics and beta-amyloid (A(3) burden defined by positron emission tomography (PET) - the current in vivo gold standard for detection of cortical All, thus supporting GEPCI as a potential surrogate marker for All imaging a known biomarker of early AD. Remarkably, the data show significant correlations not only in the areas of high A beta accumulation (e.g. precuneus) but also in some areas of medial temporal lobe (e.g. parahippocampal cortex), where A beta accumulation is relatively low.Conclusion: We have demonstrated that GEPCI provides a new approach for the in vivo evaluation of AD related tissue pathology in the preclinical and early symptomatic stages of AD. Since MRI is a widely available technology, the GEPCI surrogate markers of AD pathology have a potential for improving the quality of AD diagnostic, and the evaluation of new disease-modifying therapies.

The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods

Overview of ADNI MRI

Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative

The Alzheimer's Disease Neuroimaging Initiative Positron Emission Tomography Core

Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease

Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)

Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI)

Arterial spin labeling perfusion MRI in the Alzheimer's Disease Neuroimaging Initiative: Past, present, and future

Categorical and Correlational Analyses of Baseline Fluorodeoxyglucose Positron Emission Tomography Images from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

IC-03-06: Six Month MRI Gray Matter Declines in Alzheimer's Dementia Evaluated by Voxel-Based Morphometry with Multivariate Network Analysis: Preliminary Findings from the ADNI Study

Twelve-month Metabolic Declines in Probable Alzheimer's Disease and Amnestic Mild Cognitive Impairment Assessed Using an Empirically Pre-Defined Statistical Region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative

Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD

The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives

P4‐053: Relationship Between Longitudinal, Structural Magnetic Resonance Imaging and [18f]fluorodeoxyglucose Positron Emission Tomography Data from the Alzheimer'S Disease Neuroimaging Initiative Study

Magnetic resonance imaging in Alzheimer’s disease and mild cognitive impairment

In Vivo Detection of Microstructural Correlates of Brain Pathology in Preclinical and Early Alzheimer Disease with Magnetic Resonance Imaging.

O1-02-06: Twelve-month Cerebral Metabolic Declines in Probable Alzheimer's Disease and Amnestic Mild Cognitive Impairment: Preliminary Findings from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

Magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment

Relationship Between Longitudinal, Structural Magnetic Resonance Imaging and [18f]fluorodeoxyglucose Positron Emission Tomography Data From The Alzheimer'S Disease Neuroimaging Initiative Study

P1‐216: Six Month MRI Gray Matter Declines in Alzheimer's Dementia Evaluated by Voxel‐based Morphometry with Multivariate Network Analysis: Preliminary Findings from the Alzheimer's Disease Neuroimaging Initiative

Morphometry of medial temporal lobe subregions using high-resolution T2-weighted MRI in ADNI3: Why, how, and what's next?